Skip to main content
SpringerLink
Log in

Chemoprevention of Lung Cancer: Current Status and Future Prospects

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Lung cancer is the leading cause of cancer death in the United States. The current mainstays of lung cancer therapy are surgery, radiation and chemotherapy. These interventions have produced slight declines in mortality rates in the last 5 years however, it appears unlikely that marked improvements will occur in the near future. This grim overview argues strongly for new, emerging approaches for controlling this disease. Chemoprevention is the use of specific natural or synthetic substances with the objective of reversing, suppressing or preventing carcinogenic progression to invasive cancer. Whether primary, secondary or tertiary settings, prevention has the highest potential to improve the dismal statistics associated with this cancer. Several randomized clinical or translational chemoprevention trials have been conducted. All have so far produced either neutral or harmful primary endpoint results showing that lung cancer was not prevented by alpha-tocopheral, beta-carotene, retinal, retinyl palmitate, N-acetylcysteine or isotretinoin in smokers. Secondary results supporting treatment with isotretinoin in 'never' and former smokers and data from prevention trials involving selenium and vitamin E however, are encouraging and offer a promising direction for future clinical study. Other areas of promise for future lung cancer chemoprevention study include the study of molecular markers of risk and drug activity, molecular targeting study, improved imaging techniques and new drug delivery systems.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics. CA Cancer J Clin 51: 15–36, 2001

    Google Scholar 

  2. Reis L, Eisner M, Kosary C et al.: SEER Cancer Statistics Review, 1973–1997, National Cancer Institute, Bethesda, MD, 2000

    Google Scholar 

  3. Ginsberg RJ, Vokes EE, Rosenzweig K: Cancer of the lung. Non-small-cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology, 6th edn, Lippincott, Philadelphia, 2001, pp 925–983

    Google Scholar 

  4. Schottenfield D: Epidemiology of lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT (eds) Lung Cancer Principles and Practice. Lippincott-Raven, Philadelphia, 1996, pp 305–321

    Google Scholar 

  5. Lippman SM, Benner SE, Hong WK: Cancer chemoprevention. J Clin Oncol 12: 851–873, 1994

    Google Scholar 

  6. Lippman SM, Hong WK: Molecular markers of the risk of oral cancer. N Engl J Med 344: 1323–1326, 2001

    Google Scholar 

  7. Auerbach O, Stout AP, Hammond EC et al.: Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. N Eng J Med 265: 253–267, 1961

    Google Scholar 

  8. Mao L, Lee JS, Kurie JM et al.: Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 89: 857–862, 1997

    Google Scholar 

  9. Wistuba II, Lam S, Behrens C et al.: Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 89: 1366–1373, 1997

    Google Scholar 

  10. Hong WK, Sporn MB: Recent advances in chemoprevention of cancer. Science 278: 1073–1077, 1997

    Google Scholar 

  11. Mavne ST, Lippman SM: Retinoids, carotenoids and micronutrients. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology, 6th edn, Lippincott-Raven, Philadelphia, 1997, pp 575–590

    Google Scholar 

  12. Krinsky NI: Actions of carotenoids in biologic systems. Ann Rev Nutr 13: 561, 1993

    Google Scholar 

  13. Peto R, Doll R, Buckley JD et al.: Can dietary β-carotene materially reduce human cancer rates? Nature 290: 201–209, 1981

    Google Scholar 

  14. Floyd RA: Role of free radicals in carcinogenesis and brain ischemia. FASEB J 4: 2587, 1990

    Google Scholar 

  15. Chew BP, Wong TS, Shultz TD et al.: Effects of conjugated dienoic derivatives of linoleic acid and beta-carotene in modulating lymphocyte and macrophage function. Anticancer Res 17: 1099–1106, 1997

    Google Scholar 

  16. Murata T, Tamai H, Morinobu T et al.: Effect of long-term administration of beta-carotene on lymphocyte subsets in humans. Am J Clin Nutr 60: 597–602, 1994

    Google Scholar 

  17. Toba T, Shidoji Y, Fujii J et al.: Growth suppression and induction of heat-shock protein-70 by 9-cis beta-carotene in cervical dysplasia-derived cells. Life Sci 61: 839–845, 1997

    Google Scholar 

  18. Muto Y, Fujii J, Shidoji Y et al.: Growth retardation in human cervical dysplasia-derived cell lines by beta-carotene through down-regulation of epidermal growth factor receptor. Amer J Clin Nutr 62(Suppl 6): 1535S–1540S, 1995

    Google Scholar 

  19. Mangelsdorf DJ, Umesono K, Evans RM: The retinoid receptors. In: Sporn MB, Roberts AB, Goodman DS (eds) The Retinoids: Biology, Chemistry and Medicine, 2nd edn, Raven Press, New York, 1994, pp 319–349

    Google Scholar 

  20. Mangelsdorf DJ, Thummel C, Beato M et al.: The nuclear receptor superfamily: The second decade. Cell 83: 835–839, 1995

    Google Scholar 

  21. Chambon P: A decade of molecular biology of retinoic acid receptors. FASEB J 10: 940–954, 1996

    Google Scholar 

  22. Zelent A, Mendelson C, Kastner P et al.: Differentially expressed isoforms of the mouse retinoic acid receptor beta are generated by usage of two promoters and alternative splicing. EMBO J 10: 71–81, 1991

    Google Scholar 

  23. Napgal S, Zelent A, Chambon P: RAR-beta-4, a retinoic acid receptor isoform is generated from RAR-beta-2 by alternative splicing and usage of a CUG initiator codon. Proc Natl Acad Sci USA 89: 2718–2722, 1992

    Google Scholar 

  24. Xu XC, Roy JY, Lee JS et al.: Differential expression of nuclear retinoic acid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res 54: 3580–3587, 1994

    Google Scholar 

  25. Lotan R, Sozzi G, Ro J et al.: Selective suppression of retinoic acid receptor β (RAR-β) expression in squamous metaplasia and in non-small cell lung cancers (NSCLC) compared to normal bronchial epithelium. Proc Amer Soc Clin Oncol 14: 165, 1995

    Google Scholar 

  26. Lotan R, Xu X-C, Lippman SM et al.: Suppression of retinoic acid receptor-b in premalignant oral lesions and its upregulation by isotretinoin. N Engl J Med 332: 1405–1410, 1995

    Google Scholar 

  27. Lotan R: Retinoids and chemoprevention of aerodigestive tract cancer. Cancer Metastasis Rev 16: 349–356, 1997

    Google Scholar 

  28. Frangioni JV, Moghal N, Stuart-Tilley A et al.: The DNA binding domain of retinoic acid receptor beta is required for ligand-dependent suppression of proliferation. Application of general purpose mammalian coexpression vectors. J Cell Science 107: 827–838, 1994

    Google Scholar 

  29. Khuri FR, Lotan R, Kemp B et al.: Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. J Clin Oncol 18: 2798–2804, 2000

    Google Scholar 

  30. Mariani L, Formelli F, De Palo G et al.: Chemoprevention of breast cancer with fenretinide (4-HPR): Study of long-term visual and opthalmologic tolerability. Tumori 82: 444–449, 1996

    Google Scholar 

  31. Costa A, Formelli F, Chiesa F et al.: Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 54: 2032S–2037S, 1994

    Google Scholar 

  32. Dimery IW, Hong WK, Lee JJ et al.: Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity. Ann Onc 8: 85–89, 1997

    Google Scholar 

  33. Singh DK, Lippman SM: Cancer chemoprevention part 1: Retinoids and carotenoids and other classic antioxidants. Oncology 11: 1643–1658, 1998

    Google Scholar 

  34. Workshop report: Biomarkers in cancer chemoprevention. In: Miller AB, Bartsch H, Boffetta P, Dragsted L, Vainio H (eds) Biomarkers in Cancer Chemoprevention. IARC Scientific Publications No. 154, Lyon, 2001, pp 1–12

  35. Hong WK, Lippman SM, Hittelman WN et al.: Retinoid chemoprevention of aerodigestive cancer: From basic research to the clinic. Clin Cancer Res 1: 677–686, 1995

    Google Scholar 

  36. Lippman SM, Lee JS, Lotan R et al.: Biomarkers as intermediate endpoints in chemoprevention trials. J Natl Cancer Inst 82: 555–560, 1990

    Google Scholar 

  37. Greenwald P: Cancer risk factors for selecting cohorts for large-scale chemoprevention trials. J Cell Biochem 25(Suppl): 29–36, 1996

    Google Scholar 

  38. Kelloff GJ, Boone CW, Crowell JA et al.: Risk biomarkers and current strategies for cancer chemoprevention. J Cell Biochem 25(Suppl): 1–14, 1996

    Google Scholar 

  39. Loeb LA, Ernster VL, Warner KE et al.: Smoking and lung cancer: An overview. Cancer Res 44: 5940–5958, 1984

    Google Scholar 

  40. Kerr KM: Adenomatous hyperplasia and the origin of peripheral adenocarcinoma of the lung. In: Corrin B (ed) Pathology of Lung Tumors. Churchill Livingstone, Edinburgh, 1997, pp 119–134

    Google Scholar 

  41. Miller RR, Nelems B, Evans KG et al.: Glandular neoplasia of the lung. A proposed analogy to colonic tumors. Cancer 61: 1009–1014, 1988

    Google Scholar 

  42. Travis WD, Colby TV, Corrin B et al. (eds): Histological typing of lung and pleural tumors. WHO International Histological Classification of Tumors, 3rd edn, Springer, Berlin, 1999

  43. Sekido Y, Fong KW, Minna JD: Cancer of the lung. Molecular biology of lung cancer. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology, 6th edn, Lippincott-Raven, Philadelphia, 2001, pp 917–925

    Google Scholar 

  44. Tockman MS: Lung cancer: Chemoprevention and intermediate effect markers. In: Miller AB, Bartsch H, Boffetta P, Dragsted L, Vainio H (eds) Biomarkers in Cancer Chemoprevention. IARC Scientific Publications No. 154, Lyon, 2001, pp 257–270

  45. Alpha-tocopherol, Beta-Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. New Engl J Med 330: 1029–1035, 1994

    Google Scholar 

  46. Omenn GS, Goodman GE, Thornquist MD et al.: Effects of a combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334: 1150–1155, 1996

    Google Scholar 

  47. Hennekens CH, Buring JE, Manson JE et al.: Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 334: 1145–1149, 1996

    Google Scholar 

  48. Paolini M, Cantelli-Forti G, Perocco P et al.: Co-carcinogenic effect of β-carotene. Nature 398: 760–761, 1999 (scientific correspondence)

    Google Scholar 

  49. Perocco P, Paolini M, Mazzulo M et al.: β-Carotene as enhancer of cell transforming activity of powerful carcinogens and cigarette-smoke condensate on BALB/c 3T3 cells in vitro. Mutat Res 440: 83–90, 1999

    Google Scholar 

  50. Wang X-D, Liu C, Bronson RT et al.: Retinoid signaling and activator protein-1 expression in ferrets given β-carotene supplements and exposed to tobacco smoke. J Natl Cancer Inst 91: 60–66, 1999

    Google Scholar 

  51. Salgo MG, Cueto R, Winston GW et al.: Beta-carotene and its oxidation products have different effects on microsome-mediated binding of benzo(a)pyrene to DNA. Free Radic Biol Med 26: 162–173, 1999

    Google Scholar 

  52. Lee JS, Lippman SM, Benner SE et al.: Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous neoplasia. J Clin Oncol 12: 937–945, 1994

    Google Scholar 

  53. Kurie JM, Lee JS, Khuri FR et al.: N-(4-Hydroxyphenyl) retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 6: 2973–2979, 2000

    Google Scholar 

  54. Arnold AM, Browman GP, Levine MN et al.: The effect of the synthetic retinoid etretinate on sputum cytology: Results from a randomized trial. Br J Cancer 65: 737–743, 1992

    Google Scholar 

  55. McLarty JW, Holiday DB, Girard WM et al.: Beta-carotene, vitamin A, and lung cancer chemoprevention: Results of an intermediate endpoint study. Am J Clin Nutr 62: 1431S–1438S, 1995

    Google Scholar 

  56. Heimburger DC, Alexander CB, Birch R et al.: Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12. Report of a preliminary randomized double-blind intervention trial. J Am Med Ass 259: 1525–1530, 1988

    Google Scholar 

  57. Kurie JM, Lotan R, Lee JS et al.: Randomized, placebo-controlled trial of 9-cis retinoic acid (9cRA) versus 13-cis retinoic acid (13cRA) plus alpha-tocopherol (AT) in the reversal of biomarkers of bronchial preneoplasia in former smokers (unpublished data)

  58. Pastorino U, Infante M, Maioli M et al.: Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 11: 1216–1222, 1993

    Google Scholar 

  59. van Zandwijk N, Dalesio O, Pastorino U et al.: EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 92: 977–986, 2000

    Google Scholar 

  60. Lippman SM, Lee JJ, Karp DD et al.: Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 93: 605–618, 2001

    Google Scholar 

  61. Mayne ST, Cartmel B, Baum M et al.: Randomized trial of supplemental β-carotene to prevent second head and neck cancer. Cancer Res 61: 1457–1463, 2001

    Google Scholar 

  62. Clark LC, Combs GF Jr, Turnbull BW et al.: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 276: 1957–1963, 1996

    Google Scholar 

  63. Blot WJ, Li JY, Taylor PR et al.: Linxian nutrition intervention trials: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 85: 1483–1492, 1993

    Google Scholar 

  64. Lippman SM, Lee JJ, Sabichi AL: Cancer chemoprevention: Progress and promise. J Natl Cancer Inst 90: 1514–1528, 1998

    Google Scholar 

  65. Virmani AK, Rathi A, Zochbauer-Muller S et al.: Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 92: 1303–1307, 2000

    Google Scholar 

  66. Ravi RK, Scott FM, Cuttitta F et al.: Induction of gastrin-releasing peptide by all-trans retinoic acid in small-cell lung cancer cells. Oncol Rep 5: 497–501, 1998

    Google Scholar 

  67. Siegfried JM, DeMichele MA, Hunt JD et al.: Expression of mRNA for gastrin-releasing peptide receptor by human bronchial epithelial cells: Association with prolonged tobacco exposure and responsiveness to Bombesin-like peptides. Am J Respir Crit Care Med 156: 358–366, 1997

    Google Scholar 

  68. Shureiqi I, Lippman SM: Lipoxygenase modulation to reverse carcinogenesis. Cancer Res 61: 6307–6312, 2001

    Google Scholar 

  69. Manna SK, Aggarwal BB: All-trans-retinoic acid upregulates TNF receptors and potentiates TNF-induced activation of nuclear factors-kappaB, activated protein-1 and apotopsis in human lung cancer cells. Oncogene 19: 2110–2119, 2000

    Google Scholar 

  70. Khuri FR, Wu H, Lee JJ et al.: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small-cell lung cancer. Clin Cancer Res 7: 861–867, 2001

    Google Scholar 

  71. Pei XH, Nakanishi Y, Takayama K et al.: Benzo[a]pyrene activates the human p53 gene through induction of nuclear factor kappaB activity. J Biol Chem 274: 35240–35246, 1999

    Google Scholar 

  72. Zou Y, Zong G, Ling YH et al.: Effective treatment of early endobronchial cancer with regional administration of liposome–p53 complexes. J Natl Cancer Inst 90: 1130–1137, 1998

    Google Scholar 

  73. Xu XC, Lee JS, Lee JS et al.: Nuclear retinoid receptor beta in bronchial epithelium of smokers before and during chemoprevention. J Natl Cancer Inst 91: 1317–1321, 1999

    Google Scholar 

  74. Sun SY, Yue P, Dawson MI et al.: Differential effects of synthetic nuclear retionoid receptor-selective retinoids on the growth of human non-small-cell lung carcinoma cells. Cancer Res 57: 4931–4939, 1997

    Google Scholar 

  75. Ayoub J, Jean-Francois R, Cormier Y et al.: Placebo-controlled trial of 13-cis retinoic acid activity on retinoic acid receptor-beta expression in a population at high risk: Implications for chemoprevention. J Clin Oncol 17: 3546–3552, 1999

    Google Scholar 

  76. Mao L, Lee JS, Kurie JM et al.: Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 89: 857–862, 1997

    Google Scholar 

  77. Kim YH, Dohi DF, Zou CP et al.: Retinoid refractoriness occurs during lung carcinogenesis despite functional retinoid receptors. Cancer Res 55: 5603–5610, 1995

    Google Scholar 

  78. Hong WK, Spitz MR, Lippman SM: Cancer chemoprevention in the 21st century: Genetics, risk modeling and molecular targets. J Clin Oncol 18: 9s–18s, 2000

    Google Scholar 

  79. Burbee DG, Forgacs E, Zochbauer-Muller S et al.: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93: 691–699, 2001

    Google Scholar 

  80. Zochbauer-Muller S, Fong KM, Maitra A et al.: 5´ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 61: 3581–3585, 2001

    Google Scholar 

  81. Lippman SM, Spitz MR: Lung cancer chemoprevention: An integrated approach. J Clin Oncol 19: 74s–82s, 2001

    Google Scholar 

  82. Henschke CI, McCauley DI, Yankelevitz DF et al.: Early lung cancer action project. Overall design and findings from baseline screening. Lancet 354: 99–105, 1999

    Google Scholar 

  83. Kaneko M, Eguchi K, Ohmatsu H et al.: Peripheral lung cancer: Screening and detection with low-dose spiral CT versus radiography. Radiology 201: 798–802, 1996

    Google Scholar 

  84. Sone S, Li F, Yang ZG et al.: Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer 84: 25–32, 2001

    Google Scholar 

  85. Wattenburg LW, Wiedmann TS, Estensen RD et al.: Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res 57: 5489–5492, 1997

    Google Scholar 

  86. Parthasarathy R, Gilbert B, Mehta K: Aerosol delivery of liposomal all-trans-retinoic acid to the lungs. Cancer Chemother Pharmacol 43: 277–283, 1999

    Google Scholar 

  87. Mulshine JL, DeLuca LM, Dedrick RL: Regional delivery of retinoids. In: Martinet Y, Martinet N, Vignaud JM et al. (eds) Clinical and Biological Basis of Lung Cancer Chemoprevention. Birkhauser, Basal, Switzerland, 1998, pp 273–284

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Bioimmunotherapy and Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

    Victor Cohen & Fadlo R. Khuri

Authors
  1. Victor Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fadlo R. Khuri
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cohen, V., Khuri, F.R. Chemoprevention of Lung Cancer: Current Status and Future Prospects. Cancer Metastasis Rev 21, 349–362 (2002). https://doi.org/10.1023/A:1021223313546

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1021223313546

Search

Navigation